Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

AbbVie Inc (ABBV)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow AbbVie's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
164.66 +0.41    +0.25%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
164.99
+0.33
+0.20%
19:46:55 - Real-time Data
  • Volume: 4,479,202
  • Bid/Ask: 162.92 / 167.90
  • Day's Range: 164.43 - 167.44
Type:  Equity
Market:  United States
AbbVie 164.66 +0.41 +0.25%

AbbVie Inc Company Profile

 
Get an in-depth profile of AbbVie Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

50000

Equity Type

ORD

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Contact Information

Address 1 North Waukegan Road
North Chicago, 60064-6400
United States
Phone 847 932 7900
Fax -
Web www.abbvie.com

Top Executives

Name Age Since Title
Richard A. Gonzalez 67 2013 Chairman & CEO
Edward Joseph Rapp 65 2013 Independent Director
William H. L. Burnside 71 2013 Independent Director
Roxanne S. Austin 62 2013 Independent Director
Glenn F. Tilton 75 2013 Lead Independent Director
Thomas Craig Freyman 69 2020 Independent Director
Robert J. Alpern 72 2013 Independent Director
Frederick H. Waddell 69 2013 Independent Director
Rebecca B. Roberts 70 2018 Independent Director
Melody Boone Meyer 65 2017 Independent Director
Brett J. Hart 53 2016 Independent Director
Susan E. Quaggin 60 2023 Independnet Director
Jennifer L. Davis 52 2023 Independnet Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

ABBV Comments

Write your thoughts about AbbVie Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
kyle wills
kyle wills Sep 01, 2021 13:07
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
why the drop today?
Reply
0 0
Report
kyle wills
kyle wills Oct 21, 2020 10:25
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
going up?
Reply
0 0
Report
kyle wills
kyle wills Oct 21, 2020 10:25
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
going up?
Reply
0 0
Report
Evan Soukas
Evan Soukas Oct 16, 2018 21:22
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Canopy is the sleeping giant right now. Today was a test, and almost everyone saw red at the end of the day, except for MMEN. Tomorrow will be a surprise for everyone who's perceptions about Canopy were blemished after today's closing bell.
Reply
1 9
Report
lude crude
lude crude Oct 16, 2018 21:22
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why are you here commenting on canooy evan. This ticker is ABBV.
Reply
4 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email